News Related to MPS II

Related coverage linked through entity extraction aliases.

REGENXBIO Faces Class Action After FDA Clinical Holds on RGX-111 and RGX-121

Mar 20, 2026

A class action lawsuit was filed against REGENXBIO covering the period from February 9, 2022 to January 27, 2026, following FDA clinical holds on gene therapies RGX-111 and RGX-121 after a CNS tumor was discovered in a trial participant.

FDA Places Clinical Holds on Regenxbio Gene Therapies for Rare Metabolic Disorders

Jan 29, 2026

The FDA placed clinical holds on Regenxbio's RGX-111 and RGX-121 gene therapies following a tumor case in an MPS I patient. The company's stock fell nearly 18% on the news.